BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results
POMPANO BEACH, FL, August 14, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Preliminary Financial […]
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 29, 2025 – PRISM MediaWire – BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on […]
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced […]
BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results
POMPANO BEACH, FL, May 12, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today reported preliminary financial results for the first quarter ended March 31, 2025. The Company will host a webcast and conference call […]
“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have […]
BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30,2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its […]